Search results for: d842V

30 03, 2021

Avapritinib in PDGFRA D842V GIST

By |2021-03-30T14:17:27-04:00March 30th, 2021|Global, Video|

This video deals with the mechanism of avapritinib in GIST, current outcomes and challenges with PDGFRA D842V mutated GIST presented by Dr. Sameer Rastogi, All India Institute of Medical Sciences, New Delhi, India..

19 04, 2023

NCCN GIST Guidelines 2023 – What You Need to Know as a GIST Patient

By |2023-06-04T12:00:20-04:00April 19th, 2023|Advocacy, News, Patient Support|

NCCN recently updated the clinical practice guidelines in oncology for medical professionals for several types of cancer including GIST. These guidelines are a set of evidence-based recommendations for the diagnosis, treatment, and management of various types of cancer and define the recommendations for management, care, and treatment of all cancers in the US. What do you need to know?

30 07, 2021

Actualización realizada por dos prestigiosos especialistas internacionales en GIST

By |2021-07-30T11:03:57-04:00July 30th, 2021|Global, News, Research|

Publicado por Colectivo GIST España - Concluimos el mes dedicado a la concienciación del sarcoma & GIST publicando una actualización del tratamiento para los tumores GIST avanzados.

18 09, 2020

New Horizons GIST 2020

By |2020-09-18T11:27:11-04:00September 18th, 2020|Advocacy, Global, News|

The New Horizons GIST 2020 Virtual Meeting kicked off on Thursday September 10th at 8am EST. Meeting since 2003, these patient advocates for various cancers split off to a GIST-only meeting several years ago. This year’s meeting, originally planned for Berlin, Germany, was held virtually September 10-12th.

30 06, 2020

Blueprint Medicines Announces Publication in The Lancet Oncology

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

15 05, 2020

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top